Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical‐stage, immuno‐oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel, non‐chemotherapy, immune‐enhanced combination treatments for patients with solid tumor cancers. Checkpoint’s broad pipeline consists of fully‐human, immuno‐oncology and checkpoint inhibitor antibodies licensed from the Dana‐Farber Cancer Institute that target programmed death‐ligand 1 (“PD‐L1”); glucocorticoid‐induced TNFR‐related protein (“GITR”); and carbonic anhydrase IX (“CAIX”). In addition, Checkpoint is developing three oral, small‐molecule, targeted anti‐cancer agents that inhibit epidermal growth‐factor receptor (“EGFR”) mutations, the bromodomain and extra‐terminal (“BET”) protein BRD4, and poly (ADP‐ribose) polymerase (“PARP”). Checkpoint will also seek to expand its pipeline to create additional proprietary combination therapies that leverage the immune system and complementary mechanisms. Checkpoint is a majority controlled subsidiary of Fortress Biotech, Inc.
- TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting
- Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
- Posting of UK Annual Report and Accounts & Notice of AGM